No significant differences were observed between the CPF4 and CPF2 groups in terms of age, primary tumor location, stage, p16 status, cancer treatment history (whether OP was performed), time interval since the last use of cisplatin (whether less than six months), or the use of IO therapy. This evidence concerns the gene CYP4F2 and cancer.